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Endometrial cancer arising in adenomyosis (EC-AIA) is a rare form of uterine cancer. A 53-year-old Japanese postmeno-
pausal female was referred to our outpatient clinic for adenomyosis. After the 4-year follow-up, she presented with an in-
creased vaginal discharge. Endometrial curettage demonstrated either atypical endometrial hyperplasia or well-differentiated
endometrioid carcinoma. Positron emission tomography/computed tomography revealed multiple pulmonary metastases, pel-
vic bone metastases, para-aortic node metastases, and uterine tumor as the primary lesion. She was clinically diagnosed with
stage IVB endometrial cancer. Accordingly, total abdominal hysterectomy and bilateral salpingo-oophorectomy were per-
formed. Macroscopic findings of the resected uterus were difficult to distinguish from ordinal adenomyosis. Microscopically,
diffuse endometrioid carcinoma (grade 2) occupied the entire uterine body, coexisting with adenomyosis. Postoperatively,
chemotherapy and zoledronic acid administration were initiated, which are ongoing till date. The case highlights that EC-
AIA, a rare but aggressive disease, should be considered when managing patients with adenomyosis.
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Introduction
Adenomyosis is one of the most common benign dis-
eases of the uterus and is defined as ectopic endometrio-
sis invading the uterine myometrium. While endometrial
cancer coexisting with adenomyosis (EC-A) is a frequent
occurrence, the malignant transformation of adeno-
myosis, that is, endometrial cancer arising in adeno-
myosis (EC-AIA), is considered to be a rare event. Here,
we report a case of an advanced EC-AIA based on the
clinical features of the patient, although it did not fulfill
the classical histological criteria.
Case
A 53-year-old Japanese postmenopausal female was re-
ferred to our outpatient clinic for adenomyosis. She had
been diagnosed with adenomyosis by occasional mag-
netic resonance imaging (MRI) at an internal department.
Without any interval change, the patient was followed-up
at either 6-month or 1-year interval to monitor for any
changes in status. After the 4-year follow-up, she pre-
sented with an increased vaginal discharge since 10 days.
Endometrial cytology raised a suspicion of adenocarci-
noma. Total curettage of the endometrium under anesthe-
sia revealed either atypical endometrial hyperplasia or
well-differentiated endometrioid carcinoma. However,
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Fig.　1　(a) Magnetic resonance imaging (MRI; T2-weighted image) in the sagittal view when the 
patient was initially referred to the institute; diffusely thickened myometrium with low signal intensity 
indicates the presence of adenomyosis. (b) MRI under the same condition when the patient was diag-
nosed with endometrial cancer. Although uterus size does not show considerable change, the signal 
intensity in (b) appears higher than that in (a).
MRI indicated a suspicious image of the pelvic bone me-
tastasis (bilateral pubic and sacral bone) despite no con-
siderable change in the uterine size (Fig. 1). After confir-
mation using positron emission tomography/computed
tomography (PET/CT), which revealed multiple pulmo-
nary metastases, pelvic bone (bilateral pubic and sacral
bone) metastases, para-aortic node metastases, and uter-
ine tumor as primary lesions, she was clinically diag-
nosed with stage IVB endometrial cancer (Fig. 2). Ac-
cordingly, total abdominal hysterectomy and bilateral
salpingo-oophorectomy were performed. The surgical
findings revealed small amount of serous ascites, over
newborn-head-sized enlarged uterus with smooth surface
without adhesion, normal appearance of the ovaries and
tubes, and no apparent peritoneal dissemination. Macro-
scopically, the resected uterus exhibited a diffuse-
thickness myometrium (4-5 cm in thickness), which was
difficult to distinguish from ordinal adenomyosis, and a
minimal endometrial lesion at the fundus of the uterus (5
mm) (Fig. 3). Histologically, the resected specimens re-
vealed that diffuse-type endometrioid carcinoma occu-
pied the entire uterine body (depth of the invasion, 45
mm/45 mm). The endometrium appears thin and incon-
spicuous and is mostly replaced by intraepithelial carci-
noma, except for the lesion observed at the fundus
wherein aberrant glands with eosinophilic papillary nest
in the lumen were predominantly observed, along with
small foci of the solid growth component with eosino-
philic cytoplasm and milder nuclear atypia (Fig. 4 ) .
Myometrial lesions were diffuse and primarily comprised
two patterns: in situ lesions that replaced the glands of
adenomyosis and invasive lesions with microcystic, elon-
gated, and fragmented pattern (accompanied with psam-
moma bodies). The depth of myometrial invasion was
mostly just beneath the serosa, although partly exposed
microscopically. Further, small parts of benign adeno-
myosis coexisted (Fig. 5). Furthermore, the cervical inva-
sion and lymphatic spread in the adnexa were observed.
The immnohistochemical staining for vimentin was fo-
cally positive, whereas it was negative for p53 (wild-
type), estrogen receptor, and progesterone receptor.
The patient’s postoperative course was uneventful.
Chemotherapy with paclitaxel plus carboplatin was initi-
ated on postoperative day 13 at the 3-week interval for
six cycles; no major adverse events were observed during
the chemotherapy. In addition, she was administered
zoledronic acid (4 mg/body) every 4 weeks. After six cy-
cles of chemotherapy, PET/CT revealed a reduced size of
pulmonary metastases (partial response). Subsequently,
three additional cycles of the same regimen were admin-
istered. Chest CT for reevaluation revealed small residual
lesions of pulmonary metastases. Finally, the chemother-
apy regimen was changed to doxorubicin combined with
cisplatin, and the treatment is ongoing till date.
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Fig.　2　Positron emission tomography/computed tomography
demonstrates multiple pulmonary metastases (a), para-aortic node 
metastases (b), and pelvic bone metastases (c). Arrows: each le-
sion.
Fig.　3　The macroscopic view of the resected uterus (a) and its sagittal section (b). The uterus shows 
the diffuse-thickness myometrium, which is difficult to distinguish from ordinal adenomyosis. The en-
dometrium was thin, except for a minimal lesion observed at the fundus (arrow).
Fig.　4　A high power view of the neoplastic glands show floating 
eosinophilic cancer nests (H&E; magnification, ×100).
Discussion
The malignant transformation of endometriosis is well-
established carcinogenesis in ovarian cancer, especially
for clear cell and endometrioid types. Reportedly, the
malignant transformation occurs in approximately 1 %
of ovarian endometriosis cases１）. However, the malignant
transformation of adenomyosis into endometrial carci-
noma is considered to be an extremely rare occurrence.
Till date, only a limited number of case reports have been
documented sporadically. In 1959, Colman proposed a
diagnostic criteria for EC-AIA, which was a modification
of that for the malignant transformation of endometriosis,
as follows: (1) cancer must not be located in the en-
dometrium or any other place in the pelvis, (2) cancer
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Fig.　5　Microscopic findings reveal that (a) diffuse-type carcinoma occupied the complete uterine 
body, partly coexisting with adenomyosis (arrow) in a loupe image; (b) a nest of cancer adjacent to 
adenomyosis in the left portion (H&E; magnification, ×40); (c) in situ lesion surrounded by the endo-
metrial stromal cells that are stained with CD-10 (immunohistochemical staining for CD-10; magnifi-
cation, ×40); and (d) invasive lesion with microcystic, elongated, and fragmented pattern accompanied 
with a psammoma body (H&E; magnification, ×100).
arises from the epithelium of adenomyosis and should
not invade from another source, and (3) endometrial stro-
mal cells surround the aberrant glands to support the di-
agnosis of adenomyosis２）. Since then, most case series
have referred these criteria. Nevertheless, the first crite-
rion “cancer must not be located in the endometrium or
other place in the pelvis” seems to inconsistently corre-
spond to the relatively aggressive nature of EC-AIA. It
has been pointed out that the prevalence of EC-AIA has
possibly been underestimated because to fulfill all the
aforementioned criteria, advanced cases of adenomyosis
have to be excluded.
Machida et al. examined 46 patients with EC-AIA in
24 studies, which were extracted from the systematic
English literature searched through web-based search en-
gines３）. They adapted the modified criteria supported by
the immunostaining results based on previous reports, al-
though the details were not explained. EC-AIA-involved-
endometrium was defined as a continuous transition from
the adenomyotic epithelium in the myometrium to adeno-
carcinoma, which extended to the endometrium. They
compared 16 patients with EC-AIA with tumors extend-
ing into the endometrium with the remaining 28 patients
with EC-AIA with tumors confined to the myometrium
(excluded 2 patients with data missing). No differences
were observed in demographics and tumor characteristics
(e.g., age, symptoms, grade, histology, and stage) and
survival outcome of the patients between the two groups.
Seventy-six percent of EC-AIA cases demonstrated en-
dometroid histology, most of which comprised grade 1 or
2 tumor.
In addition, they assessed the histopathological find-
ings and prognosis of EC-AIA compared with the control
group of EC-A and reported that EC-AIA correlated with
poor prognosis and tended to have aggressive tumor fea-
tures, including deep myometrial invasion, advanced
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stage, and nodal metastasis. Furthermore, most cases of
EC-AIA were negative for estrogen receptors contrary to
EC-A３）. Notably, our case demonstrated almost all the
aforementioned features corresponding EC-AIA. Diffi-
culty in early-stage detection may be one of the possible
factors for the aggressive tumor feature of EC-AIA. In
the present case, MRI image of the uterine body revealed
a higher signal intensity, which is not typical for adeno-
myosis, compared with that captured 4 years prior.
Therefore, meticulous observation for change in signal
intensity of MRI images may facilitate an early diagnosis
of EC-AIA.
Till date, the oncogenic mechanism underlying the
malignant transformation of adenomyosis remains un-
clear. The incidence of genetic mutations, including
those in the AT-rich interactive domain 1A gene
(ARDIA ) , which is often observed in endometriosis-
associated ovarian cancer, has not been reported in the
literature on EC-AIA４）. Thus, further molecular genetics-
based studies of EC-AIA are warranted to elucidate the
pathogenesis and, hopefully, develop more individual-
ized treatment strategy for this endometrial cancer sub-
type in the future.
Conclusion
In conclusion, we reported a case of advanced EC-AIA
based on the clinical and histopathological characteris-
tics. The criteria for diagnosing EC-AIA requires revi-
sion to precisely define advanced EC-AIA. Overall, this
case highlights the necessity of considering aggressive
diseases, such as EC-AIA, when following up on patients
with adenomyosis.
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